HIV :: Human genome sciences reports positive results of ccr5 mab in hiv-1

Human Genome Sciences, Inc. (Nasdaq: HGSI) today announced that the results of a Phase 1 clinical trial of HGS004 (CCR5 mAb) demonstrate that it was well tolerated and exhibited antiviral activity in patients who are infected with HIV-1, the retrovirus that causes acquired immunodeficiency syndrome (AIDS). The results were reported in San Francisco in an oral presentation at the American Society for Microbiology’s 46th Annual Conference on Antimicrobial Agents and Chemotherapy (ICAAC).

Health :: Antioxidants protect against Rocky Mountain spotted fever – tick-borne

For hikers, campers and others who enjoy the outdoors, summer can bring concerns about tick bites and related illnesses such as Rocky Mountain spotted fever. Researchers are investigating the role that antioxidants — alpha-lipoic acid and potentially others like green tea and vitamins C and E, for example – might play in preventing or treating the deadly rickettsia bacteria.

Serotonin Syndrome :: Serotonin syndrome or hyperserotonemia

Serotonin syndrome (or hyperserotonemia) is a hyperserotonergic state, that is an excess of 5-HT (serotonin) in the central nervous system. It is usually associated with high doses of serotonergic drugs, when combinations of serotonergic agents are used together, or when antidepressants are changed without an adequate washout period between drugs.

Health :: New Vaccine to Prevent Rotavirus Gastroenteritis in Infants

The Food and Drug Administration (FDA) announced the approval of RotaTeq, a live, oral, vaccine for use in preventing rotavirus gastroenteritis in infants. It is the only vaccine approved in the United States that can help protect against rotavirus, a viral infection that may cause diarrhea, vomiting, fever, and dehydration.

Influenza :: Tamiflu for Prevention of Influenza in Children

The U.S. Food & Drug Administration (FDA) approved the use of Tamiflu (oseltamivir phosphate) for prevention (prophylaxis) of seasonal influenza (“flu”) in children 1 to 12 years of age who had close contact with an infected individual. This is the first drug approved for prevention of both influenza A and B in pediatric patients.